Page 2, bottom of page, insert

--Brief Description of the Drawings

Figures 1-4 are self-explanatory X-ray powder diffraction diagrams of the 4 crystalline modifications of the calcium salts of the invention, and Figure 5 is a diagram of the amorphous salt.--

IN THE CLAIMS

Please amend the claims as follows:

1. (Amended) [Crystalline salts] A crystalline salt of 5-methyl-(6R,S)-, -(6S)- [and] or -(6R)-tetrahydrofolic acid said crystalline salt having a water of crystallization of at least one equivalent per equivalent of 5-methyltetrahydrofolic acid.

2. (Amended) [Crystalline salts] A crystalline salt according to claim 1, of 5-methyl-(6S)- [and] or -(6R)-tetrahydrofolic acid.

3. (Amended) [The] A crystalline calcium salt according to claim 1, of 5-methyl-(6S)- and -(6R)-tetrahydrofolic acid having ≥ 3 equivalents of water.

4. (Amended) [The] A crystalline calcium salt according to claim 1, of 5-methyl-(6S)-tetrahydrofolic acid with 2 theta values of 6.5, 13.3, 16.8 and 20.1 (Type I).

5. (Amended) [The] A crystalline calcium salt according to claim 1, of 5-methyl-(6S)-tetrahydrofolic acid with 2 theta values of 5.3, 6.9, 18.7 and 21.1 (Type II).

6. (Amended) [The] A crystalline calcium salt according to claim 1, of 5-methyl-(6S)-tetrahydrofolic acid with 2 theta values of 6.8, 10.2, 15.4 and 22.5 (Type III).

7. (Amended) [The] A crystalline calcium salt according to claim 1, of 5-methyl-(6S)-tetrahydrofolic acid with 2 theta values of 6.6, 15.9, 20.2 and 22. 5(Type IV).